236 related articles for article (PubMed ID: 29431018)
1. Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches.
Davidson M; Chau I
Expert Rev Anticancer Ther; 2018 Apr; 18(4):327-338. PubMed ID: 29431018
[TBL] [Abstract][Full Text] [Related]
2. Multimodality treatment for localized gastro-oesophageal cancer.
Okines AF; Cunningham D
Ann Oncol; 2010 Oct; 21 Suppl 7():vii286-93. PubMed ID: 20943630
[TBL] [Abstract][Full Text] [Related]
3. Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer.
Bystricky B; Okines AF; Cunningham D
Drugs; 2011 Mar; 71(5):541-55. PubMed ID: 21443280
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy for oesophagogastric cancer.
Lordick F; Stein HJ; Peschel C; Siewert JR
Br J Surg; 2004 May; 91(5):540-51. PubMed ID: 15122603
[TBL] [Abstract][Full Text] [Related]
5. Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study.
Trip AK; Stiekema J; Visser O; Dikken JL; Cats A; Boot H; van Sandick JW; Jansen EP; Verheij M
Acta Oncol; 2015 Nov; 54(10):1754-62. PubMed ID: 25797568
[TBL] [Abstract][Full Text] [Related]
6. Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?
Cartwright E; Keane FK; Enzinger PC; Hong T; Chau I
Am Soc Clin Oncol Educ Book; 2018 May; 38():280-291. PubMed ID: 30231360
[TBL] [Abstract][Full Text] [Related]
7. Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.
Roy AC; Shapiro J; Burge M; Karapetis CS; Pavlakis N; Segelov E; Chau I; Lordick F; Chen LT; Barbour A; Tebbutt N; Price T
Expert Rev Anticancer Ther; 2020 Apr; 20(4):305-324. PubMed ID: 32202178
[No Abstract] [Full Text] [Related]
8. Controversies in the treatment of local and locally advanced gastric and esophageal cancers.
Cohen DJ; Leichman L
J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302
[TBL] [Abstract][Full Text] [Related]
9. Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future.
Aggelis V; Cunningham D; Lordick F; Smyth EC
Ann Oncol; 2018 Jun; 29(6):1377-1385. PubMed ID: 29771279
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma.
Park I; Ryu MH; Choi YH; Kang HJ; Yook JH; Park YS; Kim HJ; Jung HY; Lee GH; Kim KC; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2013 Oct; 72(4):815-23. PubMed ID: 23921575
[TBL] [Abstract][Full Text] [Related]
11. Optimal management of resectable gastric adenocarcinoma.
Buscariollo DL; Mamon HJ
Expert Rev Anticancer Ther; 2015; 15(8):931-41. PubMed ID: 26165449
[TBL] [Abstract][Full Text] [Related]
12. For localized gastroesophageal cancer, you give chemoradiation before surgery, but then what happens?
Ajani JA; Correa AM; Swisher SG; Wu TT
J Clin Oncol; 2007 Sep; 25(27):4315-6. PubMed ID: 17878485
[No Abstract] [Full Text] [Related]
13. Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation.
Piro G; Carbone C; Santoro R; Tortora G; Melisi D
Expert Rev Mol Diagn; 2018 Apr; 18(4):357-370. PubMed ID: 29544370
[TBL] [Abstract][Full Text] [Related]
14. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer.
Deng HY; Wang WP; Wang YC; Hu WP; Ni PZ; Lin YD; Chen LQ
Eur J Cardiothorac Surg; 2017 Mar; 51(3):421-431. PubMed ID: 27694253
[TBL] [Abstract][Full Text] [Related]
16. Multimodal Anti-tumor Approaches Combined with Immunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer.
Bolm L; Käsmann L; Paysen A; Karapetis C; Rades D; Wellner UF; Keck T; Watson DI; Hummel R; Hussey DJ
Anticancer Res; 2018 Jun; 38(6):3231-3242. PubMed ID: 29848670
[TBL] [Abstract][Full Text] [Related]
17. Optimizing adjuvant therapies for the treatment of gastric cancer: with a special focus on Asia.
Sasako M
Expert Rev Anticancer Ther; 2019 Nov; 19(11):939-945. PubMed ID: 31661989
[No Abstract] [Full Text] [Related]
18. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma.
Lutz MP; Zalcberg JR; Ducreux M; Adenis A; Allum W; Aust D; Carneiro F; Grabsch HI; Laurent-Puig P; Lordick F; Möhler M; Mönig S; Obermannova R; Piessen G; Riddell A; Röcken C; Roviello F; Schneider PM; Seewald S; Smyth E; van Cutsem E; Verheij M; Wagner AD; Otto F
Eur J Cancer; 2019 May; 112():1-8. PubMed ID: 30878666
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis.
Petrelli F; Ghidini M; Barni S; Sgroi G; Passalacqua R; Tomasello G
Gastric Cancer; 2019 Mar; 22(2):245-254. PubMed ID: 30483986
[TBL] [Abstract][Full Text] [Related]
20. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer.
Lutz MP; Zalcberg JR; Ducreux M; Ajani JA; Allum W; Aust D; Bang YJ; Cascinu S; Hölscher A; Jankowski J; Jansen EP; Kisslich R; Lordick F; Mariette C; Moehler M; Oyama T; Roth A; Rueschoff J; Ruhstaller T; Seruca R; Stahl M; Sterzing F; van Cutsem E; van der Gaast A; van Lanschot J; Ychou M; Otto F;
Eur J Cancer; 2012 Nov; 48(16):2941-53. PubMed ID: 22921186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
